[go: up one dir, main page]

NI202000029A - Amidas de imidazopiridina sustituidas y su uso - Google Patents

Amidas de imidazopiridina sustituidas y su uso

Info

Publication number
NI202000029A
NI202000029A NI202000029A NI202000029A NI202000029A NI 202000029 A NI202000029 A NI 202000029A NI 202000029 A NI202000029 A NI 202000029A NI 202000029 A NI202000029 A NI 202000029A NI 202000029 A NI202000029 A NI 202000029A
Authority
NI
Nicaragua
Prior art keywords
diseases
prophylaxis
treatment
substituted imidazopyridine
amides
Prior art date
Application number
NI202000029A
Other languages
English (en)
Inventor
Meibom Daniel
Meyer Jutta
Collins Karl
Ortega Hernandez Nuria
Stampfuss Jan
Wunder Frank
Freudenberger Till
Mondritzki Thomas
Alexandra Scheerer Nina
Leineweber Kirsten
Schamberger Jens
Straub Alexander
Matthias Gericke Kersten
Kroh Walter
Lobell Mario
Münter Klaus
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI202000029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NI202000029A publication Critical patent/NI202000029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud se refiere a nuevas amidas de imidazopiridinas sustituidas de la fórmula (I), a procedimientos para su preparación, al uso de los mismos por sí solos o en combinación para el tratamiento y/o la profilaxis de enfermedades y al uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o la profilaxis de enfermedades cardiovasculares, neurológicas y del sistema nervioso central, así como enfermedades metabólicas.
NI202000029A 2017-10-24 2020-04-23 Amidas de imidazopiridina sustituidas y su uso NI202000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24

Publications (1)

Publication Number Publication Date
NI202000029A true NI202000029A (es) 2020-10-09

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000029A NI202000029A (es) 2017-10-24 2020-04-23 Amidas de imidazopiridina sustituidas y su uso

Country Status (27)

Country Link
US (1) US20200339567A1 (es)
EP (1) EP3700903A1 (es)
JP (1) JP2021500366A (es)
KR (1) KR20200076686A (es)
CN (1) CN111225917A (es)
AR (1) AR113790A1 (es)
AU (1) AU2018354785A1 (es)
BR (1) BR112020007967A2 (es)
CA (1) CA3084422A1 (es)
CL (1) CL2020001075A1 (es)
CO (1) CO2020004968A2 (es)
CR (1) CR20200173A (es)
CU (1) CU20200041A7 (es)
DO (1) DOP2020000072A (es)
EA (1) EA202091020A1 (es)
EC (1) ECSP20023043A (es)
IL (1) IL273954A (es)
JO (1) JOP20200073A1 (es)
MA (1) MA50440A (es)
MX (1) MX2020004190A (es)
NI (1) NI202000029A (es)
PE (1) PE20201280A1 (es)
PH (1) PH12020550472A1 (es)
SG (1) SG11202003641RA (es)
TW (1) TW201932462A (es)
UY (1) UY37947A (es)
WO (1) WO2019081353A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TW202504901A (zh) 2018-12-20 2025-02-01 美商英塞特公司 咪唑并嗒嗪及咪唑并吡啶化合物及其用途
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (de) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
WO2023086390A1 (en) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Methods and compositions for providing myocardial protection and treating myocardial stress and fibrosis
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE60112272T2 (de) 2000-04-27 2006-05-24 Astellas Pharma Inc. Imidazopyridin-derivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004535467A (ja) 2001-07-20 2004-11-25 オサケユイチア ユバンティア ファーマ リミティド α−２Ｂ−アドレナリン受容体が介在する疾患を治療又は予防するために有用な化合物
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US20100076194A1 (en) 2008-09-17 2010-03-25 Allergan, Inc. Substituted 3-amino-1-oxo or thioxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles are selective alpha 2b antagonists
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9000186B2 (en) * 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
BR112015001211B1 (pt) 2012-07-20 2020-12-15 Bayer Pharma Aktiengesellschaft Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
WO2014131760A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
MA40893B1 (fr) 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées

Also Published As

Publication number Publication date
PH12020550472A1 (en) 2021-03-15
AR113790A1 (es) 2020-06-10
CN111225917A (zh) 2020-06-02
JOP20200073A1 (ar) 2020-04-29
CA3084422A1 (en) 2019-05-02
BR112020007967A2 (pt) 2020-10-20
US20200339567A1 (en) 2020-10-29
CL2020001075A1 (es) 2021-01-22
UY37947A (es) 2019-05-31
JP2021500366A (ja) 2021-01-07
AU2018354785A1 (en) 2020-04-23
MA50440A (fr) 2020-09-02
WO2019081353A1 (de) 2019-05-02
DOP2020000072A (es) 2020-08-31
CU20200041A7 (es) 2021-03-11
CR20200173A (es) 2020-06-26
KR20200076686A (ko) 2020-06-29
ECSP20023043A (es) 2020-06-30
IL273954A (en) 2020-05-31
SG11202003641RA (en) 2020-05-28
PE20201280A1 (es) 2020-11-24
EA202091020A1 (ru) 2020-07-24
CO2020004968A2 (es) 2020-05-05
TW201932462A (zh) 2019-08-16
EP3700903A1 (de) 2020-09-02
MX2020004190A (es) 2020-08-03

Similar Documents

Publication Publication Date Title
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2017011851A2 (es) Compuestos novedosos
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CR20160155A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
MX2017009608A (es) Compuestos anticancerigenos.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
CO2020001506A2 (es) Nuevos compuestos